CRISPR Therapeutics’ Post

During the presentation TRACER recently gave at GOP, a Groninger enterprise award, the audience was so quiet you could hear a pin drop. When you first hear about imaging in drug development, it's mind-blowing. This may even apply to people who have worked in pharma for many years. Do you want to learn more about imaging for clinical trials? Or do you know someone who should know more about this? Let us know. Send a message or tag someone in the comments. #drugdevelopment #drugdiscovery #clinicaltrials #nuclearmedicine #contractresearch

The validation step of our drug discovery phase in Everlum Bio’s Cure Plan is where we put our promising drug candidates through the wringer, verifying and confirming their potential before they can advance to clinical trials. It's all about ensuring the initial results are reliable, reproducible, and have a real shot at becoming safe and effective treatments for each patient. And when it comes to rare diseases, the proof-of-concept phase is equally essential. This is where we demonstrate the feasibility and potential effectiveness of our novel therapeutic approaches. Want to see if Everlum can do this for you? Contacting us at everlum.bio today! #DrugDevelopment #PreclinicalResearch #RareDiseaseInnovation #Validation #RapidProofof Concept #PersonalizedMedicine #JourneyToACure

We are less than a month away from EDDC’s Annual Drug Discovery Symposium 2024 happening on 19 July 2024, Friday! This year, our esteemed speakers will speak on the following topics regarding the transformation of Drug Discovery:  1. William Chin: Evolution of Drug Discovery – Finding Drugs Then and Now  2. Jackie Hunter PhD DSc CBE FBPharmacolS FMedSci: How Bigger Data, Better Questions and AI-driven Tools are Changing Drug Discovery and Development 3. Andreas Wallnoefer: A Short Guidance on Success Factors in Drug Development 4. Alex Matter: The Challenges for Global Healthcare   A reminder that there is a closed-door networking session with the speakers after the event, for a limited number of sign-ups.    Register here: https://lnkd.in/g5x-nMsP   Check out the event webpage for more information: https://lnkd.in/gtrpdpyS  You may also download the full programme booklet on the webpage for more information on the talks and speakers.   We hope to see you there!   #EDDCsg #DrugDiscovery #DrugDevelopment #Symposium #Networking

**Please note that we have had to postpone this webinar due to external events, we will announce the new date shortly, stay tuned!** Join us for a discussion with the authors of the recently published article ‘Making Good Decisions in Early Drug Discovery’ (Drug Discovery Today June 2024). The conversation will focus on the critical elements of Decision Framing, which are key to enabling collaborative conversations and alignment with early drug discovery teams and the development of a clear decision roadmap. The approach was developed to address the challenges of decision making in drug discovery research in the face of uncertainty. The concept and tools associated with Decision Quality provide a helpful frame for team-based strategy development, scientific conversation and qualitative evaluation of plan options. During this webinar, we will discuss and answer the following questions: ✔ How is Decision Quality used to support early drug discovery? ✔ Which Decision Framing tools facilitate the development of alternative strategies and the Decision Roadmap? Registration Link: https://lnkd.in/gbQzdb9w #DecisionMaking #UncertaintyAnalysis #OnlineCourse #ProfessionalDevelopment #DecisionScience #DecisionQuality

The video Mark mentions below is great to learn more about protein degradation!

Join #OPIS at Biotech Showcase 2025 in San Francisco! We are excited to announce our participation in Biotech Showcase, taking place from January 13-15 in San Francisco, CA. Our team of experts will be on-site, ready to discuss how OPIS’s comprehensive clinical trial solutions can support your drug development journey. From early-stage trials to complex late-phase projects, we are here to help you achieve your goals with efficiency and expertise. Let’s connect! Schedule a meeting with us on the event’s partnering platform, or visit opisresearch.com to learn more about how OPIS can add value to your clinical research programs. #BiotechShowcase #ClinicalExcellence #ClinicalTrials #BiotechInnovation

I recently had the privilege of attending the ASGCT Policy Summit, and it’s evident that the industry is on the cusp of remarkable growth. With rapid scientific advancements progressing through the pipeline, we are closer than ever to addressing unmet medical needs. It’s especially encouraging to see strong engagement from various FDA divisions, working collaboratively with sponsors and policymakers. This type of cooperation is essential in transforming the vision of novel therapies—particularly for oncology and rare diseases—into reality. That said, there is still significant work ahead. Regulatory support, public policy development, and ensuring payer coverage and reimbursement remain critical areas of focus. As Rubin M., Director of Global Regulatory Affairs at Intellia Therapeutics, highlighted in his keynote, on/off-target editing analysis is a key consideration in regulatory approvals. Broken String Biosciences is well positioned to support our pharma partners in these regulatory discussions. The progress we’re witnessing as a community gives us hope that viable therapies are on the horizon. However, the journey is far from over. #ASGCTadvocacy #ASGCT #GeneTherapy #RareDisease #PolicySummit #FDA #Biotech #Innovation #HealthcareTransformation #Oncology

At @Bristol Myers Squibb, we are all in on #TargetedProteinDegradation (TPD) and its potential for patients. As one of our differentiated research platforms, we’re expanding on our legacy in TPD by exploring potential new options across a broad range of diseases. We had great discussions about these advancements during our annual European Scientific Innovation Summit this week. You can learn more about our efforts in TPD here: Science Firsthand: The pathway to drug discovery – Bristol Myers Squibb (bms.com) #BMS_Employee, #EUScientificInnovationSummit

Today, Biotrial enrolled the first subjects of a new phase I bioequivalence study. The study features a Crossover design with 75 volunteers hospitalized for 14 days in Biotrial's state-of-the-art Phase I facilities. With over 35 years of experience in conducting well-controlled clinical trials, our high recruitment capabilities enable us to quickly mobilize a large number of volunteers tailored to your study's needs. Our teams offer personalized solutions for your drug development initiatives, ensuring efficient and timely study progression. #ClinicalTrials #PhaseI #Drugdevelopment

With just over a week remaining, there’s still time to register for our upcoming webinar, hosted by Thomas Pesnot (FRSC) and featuring keynote speaker Rob Riley. The focus will be on the ADMET Toolkit for Clinical Pharmacokinetics. We’d love to have you join us! Register here: https://lnkd.in/edkmpNF5 In this webinar, we’ll cover: What is ADMET, and why is it crucial for drug discovery? Why are predicted human PK and exposure essential for success? What are the main ADMET challenges? How to design an effective screening cascade. How to anticipate and address ADMET challenges with tailored solutions.